Sanofi sees continued growth and strong financials despite a pipeline setback. Click for this updated look at SNY stock ...

Sanofi flagged a second delay to an FDA decision for its experimental multiple sclerosis drug and reported disappointing ...

French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

In 2025, drug approvals widen treatment options for chronic diseases, infections and pain, including Ozempic kidney ...

This year has been one for the books in medicine. From Ozempic’s expanded role in protecting failing kidneys to long‑acting ...

Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...

Sanofi (NASDAQ:SNY) is a French pharmaceutical firm that has been at the center of several analysts’ attention lately.

The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

Kymera jumps after phase Ib study data show KT-621 delivers strong STAT6 degradation and broad clinical activity in patients with atopic dermatitis.

RegRegon Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent for treating moderate-to-severe chronic spontaneous urticaria in patients aged 12 and above who do ...